Riceman MD, Bound M, Grivell J, et al. - In type 2 diabetes (T2D) patients, researchers ascertained the prevalence of low fecal elastase-1 (FE-1) (≤ 200 µg/g) and assessed if postprandial glycemia after a high-fat, high-carbohydrate meal could be lessened in T2DM patients with low FE-1 with pancreatic enzyme replacement therapy (PERT). Of 109 community-based patients who submitted stool samples, 10 had low FE-1 and 8 were enlisted. In a randomized, double-blind, crossover fashion, candidates were given a high-fat, high-carbohydrate meal (718kcal) with either pancrelipase (50,000 units) or placebo. Data revealed that the prevalence of low FE-1 in T2DM was 9.2%. After PERT vs placebo, no difference was found in postprandial glycemia iAUC, gastric emptying T50, or C-peptide iAUC. According to findings, decreased FE-1 in community-based T2DM patients has a comparatively low incidence; PERT in these patients does not decrease postprandial glycemia.